TrivarX (ASX:TRI) has reported positive results from its clinical trial with the Greater Los Angeles Research and Education Foundation and the Veterans Affairs Greater Los Angeles Healthcare System, evaluating its single-lead ECG algorithm for screening current major depressive episodes in veterans with suspected sleep apnea.
The trial, involving 57 of 60 enrolled participants, showed that the single-lead algorithm achieved a sensitivity of 97% and specificity of 64% for detecting cMDE, closely aligning with the performance of TrivarX's lead asset, MEB-001, which demonstrated 88% sensitivity and 68% specificity.
The study also highlighted the high prevalence of sleep disturbance, depression, and post-traumatic stress disorder in veterans, with 58% of participants diagnosed with cMDE and 72% of those also experiencing PTSD.